Perioperative pembrolizumab plus neoadjuvant chemo shows long-term efficacy in early-stage NSCLC, even in patients who do not have a pCR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results